Patents Assigned to REGENTREE, LLC
  • METHODS OF TREATING DRY EYE SYNDROME
    Publication number: 20210213103
    Abstract: Methods of treating dry eye syndrome (DES) with an effective amount of thymosin beta 4 (T?4), T?4 fragments, T?4 isoforms, T?4 derivatives, peptide agents including amino acid sequence LKKTET [SEQ ID NO:1] or LKKTNT [SEQ ID NO:2], or variants thereof are provided. The presently disclosed subject matter provides methods of increasing tear volume, increasing tear film stability, decreasing ocular surface damage, and decreasing ocular discomfort by delivering compositions of thymosin beta 4 or fragments thereof to subjects in need.
    Type: Application
    Filed: February 25, 2021
    Publication date: July 15, 2021
    Applicant: REGENTREE, LLC
    Inventors: Won Suk Yang, Sin Wook Kang, Kyoungsun Kim
  • Methods of treating dry eye syndrome
    Patent number: 10960051
    Abstract: Methods of treating dry eye syndrome (DES) with an effective amount of thymosin beta 4 (T?4), T?4 fragments, T?4 isoforms, T?4 derivatives, peptide agents including amino acid sequence LKKTET [SEQ ID NO: 1] or LKKTNT [SEQ ID NO:2], or variants thereof are provided. The presently disclosed subject matter provides methods of increasing tear volume, increasing tear film stability, decreasing ocular surface damage, and decreasing ocular discomfort by delivering compositions of thymosin beta 4 or fragments thereof to subjects in need.
    Type: Grant
    Filed: July 17, 2017
    Date of Patent: March 30, 2021
    Assignee: REGENTREE, LLC
    Inventors: Won Suk Yang, Sin Wook Kang, Kyoungsun Kim
  • METHODS OF TREATING DRY EYE SYNDROME
    Publication number: 20190240294
    Abstract: Methods of treating dry eye syndrome (DES) with an effective amount of thymosin beta 4 (T?4), T?4 fragments, T?4 isoforms, T?4 derivatives, peptide agents including amino acid sequence LKKTET [SEQ ID NO: 1] or LKKTNT [SEQ ID NO:2], or variants thereof are provided. The presently disclosed subject matter provides methods of increasing tear volume, increasing tear film stability, decreasing ocular surface damage, and decreasing ocular discomfort by delivering compositions of thymosin beta 4 or fragments thereof to subjects in need.
    Type: Application
    Filed: July 17, 2017
    Publication date: August 8, 2019
    Applicant: REGENTREE, LLC
    Inventors: Won Suk Yang, Sin Wook Kang, Kyoungsun Kim